• By ICR Secretariat
  • Posted Monday, December 4, 2017

Acorda Takes a $363M Hit as Deaths Lead to Termination of Parkinson's Drug

https://www.biospace.com/article/unique-acorda-takes-a-363m-hit-as-deaths-lead-to-termination-of-parkinson-s-drug?utm_source=Email_JS&utm_medium=Newsletter&utm_campaign=GP_20171201

"On Nov. 15, Acorda Therapeutics reported that it had ended enrollment in its Phase III clinical trial of tozadenant for Parkinson’s disease due to several patient deaths. Today, the company announced that it was discontinuing clinical development of the drug altogether.

In both the Phase IIb study and the Phase III trial, about 890 patients received tozadenant and 234 received placebo. There were five fatalities out of seven patients with sepsis, all in the tozadenant group. Agranulocytosis is an absence of white blood cells, which are key immune cells. Four of the cases of sepsis were related to agranulocytosis, two had no white blood cell counts at the time of the event and one patient had a high white blood cell count."

To read more, click here or follow the link above.